The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases

Amin Hasanvand

Received: 1 February 2022 / Accepted: 20 March 2022 / Published online: 13 April 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
Metformin can suppress gluconeogenesis and reduce blood sugar by activating adenosine monophosphate-activated protein kinase (AMPK) and inducing small heterodimer partner (SHP) expression in the liver cells. The main mechanism of metformin's action is related to its activation of the AMPK enzyme and regulation of the energy balance. AMPK is a hetero-thermic serine/threonine kinase made of a catalytic alpha subunit and two subunits of beta and a gamma regulator. This enzyme can measure the intracellular ratio of AMP/ATP. If this ratio is high, the amino acid threonine 172 available in its alpha chain would be activated by the phosphorylated liver kinase B1 (LKB1), leading to AMPK activation. Several studies have indicated that apart from its significant role in the reduction of blood glucose level, metformin activates the AMPK enzyme that in turn has various efficient impacts on the regulation of various processes, including controlling inflammatory conditions, altering the differentiation pathway of immune and non-immune cell pathways, and the amelioration of various cancers, liver diseases, inflammatory bowel disease (IBD), kidney diseases, neurological disorders, etc. Metformin's activation of AMPK enables it to control inflammatory conditions, improve oxidative status, regulate the differentiation pathways of various cells, change the pathological process in various diseases, and finally have positive therapeutic effects on them. Due to the activation of AMPK and its role in regulating several subcellular signalling pathways, metformin can be effective in altering the cells' proliferation and differentiation pathways and eventually in the prevention and treatment of certain diseases.
Introduction

Metformin is known as one of the oldest, and most widely used oral medications in the treatment of type two diabetes or diabetes mellitus (Beladi Mousavi 2012; Taleb et al. 2014). As a result of metformin’s activity, the mitochondrial respiratory chain complex (MRCC) (Baur and Birnbaum 2014) is blocked, the rate of glucose production from glycogen in liver cells is reduced, and sensitivity to insulin and glucose uptake through the activation of the adenosine monophosphate-activated protein kinase (AMPK) increases in the liver and peripheral tissues (Ismaiel et al. 2016; Mummidi et al. 2016; Wang et al. 2016). Metformin can suppress gluconeogenesis and reduce blood sugar by activating AMPK and inducing small heterodimer partner expression in the liver (Kim et al. 2008; Chanda et al. 2009). AMPK is a heterothermic serine/threonine kinase made of a catalytic alpha subunit and two subunits of beta and a gamma regulator (Oakhill et al. 2009; Hasanvand et al. 2016). This enzyme can measure the intracellular ratio of AMP/ATP. If this ratio is high, the amino acid threonine 172 available in its alpha chain would be activated by the phosphorylated liver kinase B1 (LKB1), leading to AMPK activation (Young and Zaha 2012; Hardie 2015). In other words, since it is an intracellular energy sensor, AMPK interferes with the regulation of glucose, cellular as well as whole-body energy homeostasis, and fatty acid metabolism (Shaw et al. 2005; Bright et al. 2009; Oakhill et al. 2009). Moreover, the muscle activity, physiological stress and oxidative factors are also able to activate the AMPK (Kim, Yang et al. 2016).

AMPK, metabolic and non-metabolic pathways

Several studies have examined the role of AMPK signalling pathway in various metabolic processes. This enzyme inhibits anabolic pathways (ATP consumer), and activates catabolic pathways to re-supply the cellular energy sources. The results of a study conducted by Suet Ching Chen in 2017 revealed that metformin can suppress adipogenesis through processes that are either dependent or independent of AMPK (Chen et al. 2017). Moreover, the effect of metformin independent of AMPK depends on the cell type and its evolutionary stage. Metformin in AMPK-mediated mechanisms leads to reduced liver glucose production and an increase in its consumption. AMPK is, indeed, considered as the main regulator of sugar and fat metabolisms. Ampk activation results in a diminish in the production of lipogenic enzymes, the induction of fatty acids oxidation, and a reduction in the activity of Acetyl-CoA carboxylase enzyme (Zhou et al. 2001; An and He 2016). Furthermore,
the chronic activation of AMPK will induce the expression of hexokinase and glucose carrier (Zhou et al. 2001). In a research conducted on experimental model, it was revealed that the intra-duodenum injection of metformin into these rats could reduce glucose production from liver cells via the activation of AMPK of duodenum mucosa (Duca et al. 2015). Moreover, several studies have confirmed the role of the AMPK pathway in the reduction of lipid mass of the body and improvement of NAFLD by inducing liver fatty acid oxidation (Zang et al. 2004a, b; Smith et al. 2016). It has recently been found that AMPK acts as an inhibitor of Farnesoid X receptor (FXR). FXR regulates lipid and glucose metabolism, and is involved in controlling the production and circulation of bile acids in the liver. The cultivation of liver and intestinal cells revealed that AMPK activity would inhibit FXR transcription (Brandmaier et al. 2015). It has been indicated in some studies that occurrence of intermediate fibrosis in the omental fat storage of obese people, which is associated with AMPK deactivation, results in TGF-β/SMAD3 signalling pathway induction, activation of myofibroblasts and apoptosis of adipocytes. Metformin is capable of preventing other complications and development of fibrosis via activating AMPK and suppressing the TGF-β/SMAD3 pathway (Luo et al. 2016).

AMPK is able to participate in various non-metabolic pathways, including nitric oxide synthesis and anti-inflammatory processes (Reihill et al. 2007; Salminen et al. 2011; Salt and Palmer 2012). Metformin is involved in controlling oxidative stress by controlling complex I of the mitochondrial electron transfer chain (Kinaan et al. 2015; Wiernsperger 2015) and can be effective in reducing kidney damage induced by gentamicin (Darabi and Hasannavand 2018; Hasanvand 2018). Many studies have shown that the anti-inflammatory and antioxidative stress effects of metformin in various diseases, such as rheumatoid arthritis, neuropathic pain, renal disorders and Ankylosing spondylitis (Son et al. 2014, Afshari et al. 2018, Driver et al. 2018, Qin et al. 2018a, b, Rajaei, Haybar et al. 2018). This effect of metformin is achieved via activating multiple signalling pathways, including AMPK and PI3K/AKT. Accordingly, it can attenuated the levels of inflammatory cytokines, including TNF-α, Nrf2, IL-6 and etc. (Yan, Zhou et al. 2015, Ci, Zhou et al. 2017). Furthermore, metformin reduces the levels of inflammatory cytokines by inducing stimuli caused by lipopolysaccharide, activation of AMPK, and inhibition of phosphorylation of JNK1 in macrophages (Woo, Xu et al. 2014). AMPK chemical activators such as metformin reduce the transcription of the NF-β factor and MDR1 expression in MCF-7/adr cells (Kim et al. 2011). Continuous activity of AMPK signalling inhibits this factor and its consequent inflammation (Cacicedo et al. 2004; Yang et al. 2010). Using AMPK activators, Chunfen Mo et al. indicated in a research that this enzyme has a role in stimulating the expression of the Nrf2 transcription factor. This transcription activating factor is one of the factors that are effective in antioxidant responses (Mo et al. 2014). Nrf2 targets several genes, including NQO-1, HO-1 and glutathione S-transferase (GST), hence plays a role in regulating the antioxidant system (Tkachev et al. 2011).

Different factors can activate macrophages and cause inflammatory conditions in diabetic patients. One of the most important of these factors is the AGEs (Qin et al. 2012; Jin et al. 2015). These factors have a receptor of RAGE/NF-β on the surface of the macrophages. Various investigations have revealed that RAGE signalling plays a pivotal role in inflammation caused by the activation of macrophages by AGE (Salminen et al. 2011; Huang et al. 2015). By activating AMPK, metformin is able to reduce the expression of RAGE and suppress NF-βB activity, and accordingly, reduce the expression of macrophage inflammatory cytokines, such as IL-1β, IL-6 and TGF-β. Moreover, metformin increases the expression of IL-10 anti-inflammatory cytokines (Cai et al. 2015, Zhou et al. 2016). Various investigations suggest the relationship between the formation of AGE and development of neurological disorders and inflammatory responses in diabetic patients. Ming-Min Chung indicated that the cultivation of human neural stem cells in the presence of AGE decreases the survival of these cells and increases the production of inflammatory cytokines and oxidative enzymes. Treatment with metformin results in reducing the expression of inflammatory transcription factors, such as NF-κB and IKK, and also decreasing the production of AGE (Chung et al. 2017). By phosphorylating and stimulating AMPK, metformin can increase the rate of expression of telomerase reverse transcriptase (hTERT) enzyme and postpone the aging process of endothelial cells (Karnewar et al. 2018).

The results showed that metformin could reduce the activity of MRCC-1 and eventually reduce oxygen consumption (El-Mir et al. 2000). This inhibition of MRCC-1 by metformin affects the AMP/ATP ratio and the NAD+ / NADH ratio, which prevents gluconeogenesis (Apostolova et al. 2020).

Regulation of transcription of hepatic gluconeogenesis induced by metformin has various mechanisms, such as inhibition of CREB-mediated transcription of gluconeogenic genes through breducing cyclic AMP accumulation (Miller et al. 2013; Johanns et al. 2016). In addition, activation of AMPK by metformin could reduce the expression of gluconeogenic gene. It has been suggested that decreased expression of G6pc and Pck1 may be due to separation of the CREB transcription set and mediated by AMPK activity (He et al. 2009).
AMPK and cellular differentiation

In a recent research conducted by Wei et al. the role of metformin in increasing the differentiation of dental pulp cells into odontoblast was examined. In this research, metformin could induce differentiation and mineralization of dental pulp cells and be effective in the reconstruction of palpatory ulcers via regulating AMPK activity. Moreover, the inhibition of AMPK reduced the activity of alkaline phosphatase (Qin et al. 2018a; Zhang et al. 2020). Metformin also significantly activated AMPK in bone marrow progenitor cells (BMPCs). Prescription of metformin in a time-dependent manner stimulates the differentiation of BMPCs into osteoblast by activating specific osteoblast transcription factors, such as Runx2/Cbfa1 and activating AMPK (Pulito et al. 2010). As the activation of AMPK was intensified by metformin, phosphorylation of the STAT3 transcription factor was reduced. This factor is central to the stimulation of conversion monocyte to macrophage by regulating the signalling of pro-inflammatory events and creating inflammatory micro-environment. Hence, as its phosphorylation is reduced by AMPK, this differentiation pathway is disrupted and inflammation will be more likely to be reduced (Vasamsetti et al. 2015). Moreover, the oral prescription of metformin in the systemic lupus erythematosus disease prevents the differentiation of B cells into antibody-producing plasma cells by inhibiting the mTOR/STAT3 signalling pathway (Lee et al. 2017). It has been found that metformin increases the proliferation of regulatory T cells and raises the expression of its specific transcription factor (FOXP3) by reducing the expression of STAT3 and increasing the expression of STAT5 (Passerini et al. 2008; Goodman et al. 2011; Maddur et al. 2012). This effect is simultaneously observed with reduced power of proliferation of TH17 cells. Metformin can alter the pathway of polarity of cell differentiation from the inflammatory phenotype of TH17 to the Treg inhibitory phenotype by regulating this pathway (Lee, Lee et al. 2015a, b).

Through its effect on multiple factors, the AMPK activity can alter the differentiation pathway of macrophages towards anti-inflammatory phenotype. In fact, if macrophages are stimulated by anti-inflammatory factors, AMPK phosphorylation occurs and the macrophage phenotype would be of anti-inflammatory type. Moreover, AMPK dephosphorylation occurs if macrophage is exposed to inflammatory cytokines (Sag et al. 2008). However, it was revealed, in tumor conditions, that metformin might be involved in inhibiting the spread of tumors and suppressing cancer development by altering the pathway of tumor-associated macrophages (TAMs) from phenotypes M2 to M1. Classic macrophages or M1 have pro-inflammatory activity and the alternative type or M2 has an inhibitory effect on immune responses, particularly on anti-tumor responses (Mukhtar et al. 2011; Ding et al. 2015). Chi-Fu Chiang et al. indicated that metformin-treated cancer cells increase the production of cytokines such as IL-12 and TNF-α, which act as macrophage inhibitors to the inflammatory phenotype or M1 by activating the signalling pathway of AMPK/NF-β. Moreover, the activation of this pathway reduces the production of inhibitory cytokines, such as IL-10, IL-4, IL-13 and TGF-β, and suppresses the differentiation of macrophages towards the anti-inflammatory phenotype M2. As a result of these processes, the microenvironment surrounding the cancer cells or the tumor is likely to suppress the tumor and destroy cancer cells (Chiang et al. 2017).

Activation of AMPK–mTOR via metformin inhibits the complex activity of the MRCC, which ultimately leads to cell death or inhibition of cell proliferation by growth factors (Cai et al. 2016). Akt kinase is an important kinase in human kinoma, which has three subtypes such as AKT1, AKT2, and AKT3. AKT2 subtype has been shown to play an important role in breast cancer and its proliferation and cell survival (Santi and Lee 2011). However, the increasing of expression of miR-200c and its effect on the activity pathway of AKT2, c-Myc and Bcl-2 throught by metformin therapy and its antitumor effects may indicate the anti-cancer potency of metformin and AMPK (Pulito et al. 2014; Zhang et al. 2017).

Metformin and therapeutic goals

Therapeutic actions of metformin in COVID-19

With the advent of coronavirus in 2019, many studies have been conducted with regard to its treatment. However, the ACE2 receptor has been shown to facilitate infection at the surface of coronary target cells (Guan et al. 2020, Hoffmann et al. 2020). It has been indicated that metformin activates the AMPK pathway that can ultimately prevent the virus binding to the receptor by phosphorylating the ACE2 receptor and altering its structure (Sharma, Ray et al. 2020). Studies have shown that two proteins in humans that are regulated by the mTOR signalling pathway interact with coronavirus proteins (Sharma, Ray et al. 2020). Moreover, it has been indicated that the AMPK signalling pathway can inhibit the mTOR pathway (Ramaiah 2020). Meanwhile, functional disorders of vital organs of the body, which are among the most important coronary complications, including endothelia, cardiovascular, hematological, and brain disorders, etc., are affected by oxidative stress and inflammation processes. Activation of the AMPK pathway and subsequently inhibition of mTOR, suppression of oxidative stress and inflammation, and inhibition of the increase in genes encoding
proinflammatory cytokines, enables metformin to reduce mortality in patients with confirmed COVID-19 (Kamyshnyi et al. 2021). Decreased endosome cell pH has been shown to be associated with increased maturation of coronary virion, and metformin inhibits the endocytic cycle and maturation of virions by increasing the pH level. On the other hand, it can be effective in reducing the mortality of these patients by preventing the disruption of the normal intestinal flora, (Varghese, Samuel et al. 2021). Studies have shown that metformin can have a reduced risk of death in COVID-19 patients. This effect was mediated by inhibits mTORC1 and active LKB1 by AMPK phosphorylation (Kamyshnyi et al. 2021). Recent studies have shown that the use of metformin by AMPK activation can phosphorylate ACE2 and increase the stability of ACE2 and then decrease the host cell acceptance level for SARS-CoV-2 (Bangi et al. 2020, Sharma, Ray et al. 2020, Shen et al. 2020). Induction of the AMPK signalling pathway by metformin effectively reduces and modifies neutrophil extracellular trap activity and suppresses the inflammatory response in SARS-CoV-2 (Sharma, Chang et al. 2020, Kamyshnyi et al. 2021). In addition, Esam Z. et al. Also showed that the use of metformin could reduce the risk of lung fibrosis associated with SARS-Cov-2 (Esam 2020). There are numerous other studies in this area, all of which suggest that metformin may be a useful adjunctive therapy for COVID-19 patients (Bhutta et al. 2021, Bielka et al. 2021, Ibrahim et al. 2021, Varghese, Samuel et al. 2021, Zangiabadian et al. 2021).

Therapeutic actions of metformin as an anti-cancer agent

The relationship between the spread of tumors and cell metabolism processes, particularly the role of AMPK in these processes, has been investigated in various researches over a long period of time, and their use in developing new anti-cancer strategies are being examined (Cairns et al. 2011). The mTOR signalling pathway has a significant role in controlling the translation and construction of protein, spread of lymphocyte population, tumor genesis and drug resistance (Weichhart and Saemann 2009; Witzig and Gupta 2010; Perez-Galan et al. 2011; Zoncu et al. 2011). Epidemiological investigations have shown that using metformin is associated with reduced incidence of various types of cancers including pancreatic (Li et al. 2009), breast (Currie et al. 2009), colon (Currie et al. 2009), breast (Bodmer et al. 2010), and prostate cancers (Wright and Stanford 2009). The results of different investigations have emphasized that metformin is highly likely to inhibit mTOR and perform its anti-tumor role by activating AMPK. Moreover, the AMPK Alpha subunit interacts with mitotic and cytokine regulators. This process is also associated with the suppressing role of AMPK in combating various kinds of cancers (Vazquez-Martin et al. 2009a, b; Green et al. 2010).

Moreover, another study conducted by Tao Lu et al. stated that exposure to metformin thourgh regulating AMPK-CEBPB-PDL1 signalling pathway can a significant reduction in the risk of non-small cell lung cancer (Lu et al. 2021). Also, Zhuang Luo et al. showed that metformin can induces apoptotic cytotoxicity and finally degradation thourgh AMPK/PI3K-3p-mediated in non-small cell lung cancer (Luo et al. 2019). Various research have shown that the combination therapy of metformin with anticancer drugs makes synergic anticancer effects, such as radiation (Storozhuk et al. 2013), gefitinib (Morgillo et al. 2013; Li et al. 2017), erlotinib (Wang et al. 2017), sorafenib (Groenendijk et al. 2015), car-boplatin (Liu et al. 2017), cisplatin (Lin et al. 2013), and TRAIL (Nazim et al. 2016).

Park et al. reported that metformin regulates β-catenin to reduce cell proliferation by activating AMPK in colon carcinoma (Park et al. 2019) and other study showed that in colorectal cancer cells, inhibits non-canonical Ser552 phosphorylation in β-catenin through an AMPK/PI3K/Akt activation with metformin (Amable et al. 2019). The role of AMPK and its downstream pathway in repression of protein prenylation through MVA pathway and LKB1/AMPK pathway is linked to inhibition of tumor growth has also been reported in several study (Carretero et al. 2007; Seo et al. 2020). In another study demonstrated that activating ampk by metformin attenuated tight junction assembly in intestinal epithelium and promotes expression of colonic epithelial Caco2 cells (Chen, Wang et al. 2018). Several studies have shown that activation of cells (Vazquez-Martin et al. 2009a, b; Yi et al. 2017). Metformin inhibits the progress of cells in cancer by inducing AMPK and then LKB1 levels and ultimately inhibits translation. Also, metformin reduces the phosphorylation of S6Ks and prevents mTOR activity (Sarai et al. 2019). Metformin effectively decrease the risk of proliferation and metastasis of pancreatic cancer (Oliveria et al. 2008; Ruiter et al. 2012). In addition, evidence suggests that a reduced risk of pancreatic cancer suggests that significant inhibition of mTOR may be TSC2-independent or dependent but associated with phosphorylated AMPK (Dowling et al. 2007; Gwinn et al. 2008; Mohammed et al. 2013).

Therapeutic actions of metformin as a nephroprotective agent

It has also been indicated that metformin can have a nephroprotective effect by activating the AMPK signalling pathway (Hasanvand et al. 2018). Another research revealed that AMPK activation by metformin was associated with reduced TGF-β-induced collagen production in kidney fibroblasts in mice. This factor, which is considered as one of the
important fibrogenic cytokines, plays a significant role in the pathogenesis of kidney diseases (Hills and Squires 2011; Lu et al. 2015; Hasanvand and Saberi 2018). Moreover, the positive effect of metformin in reducing the incidence of nephropathies in diabetic patients has been confirmed (Rafieian-Kopaei 2013; Dissanayake et al. 2017). This drug prevents the formation of kidney stones with its antioxidant activity (Yang et al. 2016). It has been shown that treatment with metformin, as an AMPK agonist, can well moderate mitophagia in epithelial cells of the proximal tubule of the kidney (Zhao and Sun 2020). In addition, Ya-chun Han et al. also showed that the use of metformin could decrease the risk of fibrosis in the renal interstitial tube associated with mitophagia activation via the AMPK-Pink1-Parkin pathway (Han et al. 2021). Another study showed that the use of metformin in renal nephrectomy models following renal disease could halt the progression of chronic renal disease, including renal fibrosis, and that activation of AMPK may contribute to the protective effect of metformin nephropro-technics (Borges et al. 2020). Based on several clinical trials, metformin has shown beneficial therapeutic effects on the survival of CKD patients as well as the survival of a transplanted kidney (Stephen et al. 2014; De Broe et al. 2018).

**Therapeutic actions of metformin as a neuroprotective agent**

A study has shown that stimulation of AMPK is a major molecular mechanism of “feeding behaviour” in the hypothalamus of the brain (Blanco Martinez de Morentin, Gonzalez et al. 2011). In vitro studies have shown that stimulation of AMPK reverses neuropathic allosthyxia. Moreover, metformin could diminish chemotherapy-induced neuropathic pain in animals (Taylor et al. 2013). In rat models, metformin has been shown to have antinociceptive effects on the alleviation of pain in nerves damaged by diabetes (Ma et al. 2015). Metformin administration could up-regulate the expression of intrinsic factors linked to nerve regeneration such as apolipoprotein E (ApoE) after nerve damage (Meledjian et al. 2013). It was indicated in animal models of focal cerebral ischemia studies conducted by Harada et al. that neuroprotective effects of AMPK signalling activated by metformin diminishes the glucose intolerance. Moreover, they have reported a decrease in variation in the mnemonic tests (Harada et al. 2010). Activation of AMPK could be considered as a novel therapeutic purpose for the tentative treatment of neuropathic pain (Yerra et al. 2018). It was reported that activation of TRPA1 could induce pain-related behaviors in mice (Miura et al. 2013). However, treatment with AMPK activators could attenuate these behavioral and molecular changes in the pathophysiological profile of metabolic dysfunction (Wang et al. 2018). Various studies have shown that treatment with metformin is effective in neurological diseases, including high MPTP and increased BDNF (Patil et al. 2014, Lu et al. 2016), Parkinson’s disease (Choi et al. 2010; Arbeláez-Quintero and Palacios 2017; Lu et al. 2020, Paudel et al. 2020), epilepsy (H S, Paudel et al. 2019, Demaré et al. 2021; Sanz et al. 2021, Salvati et al. 2022), traumatic brain injury (Tao et al. 2018; Taheri et al. 2019; Fan et al. 2020; Rahimi et al. 2020), neuroprotection of the heart (Zhu et al. 2018, Benjanuwatra et al. 2020, Leech et al. 2020), and preconditioning in ischemic brain injury (Wang et al. 2021a, b, c). Various studies have shown that BDNF can affect the structure of the anal sphincter (Singh and Rattan 2021, Singh, Singh et al. 2021).

**Therapeutic actions of metformin as a cardioprotective agent**

Consumption of metformin in diabetic patients is associated with a significant reduction in cardiac infarction and atherosclerosis (Matsumoto et al. 2004). With its effect on reducing the recruitment of monocytes to the vascular wall and their differentiation into inflammatory macrophages, metformin reduces the formation of atherosclerotic plaques and decreases the levels of inflammatory cytokines (Vasamsetti et al. 2015). The effects of metformin are mediated through an increase in p-AMPK and by up-regulating p-eNOS. Moreover, it improves cardiac function. The cardioprotective effects of metformin are independent of its anti-hyperglycemic effects. Moreover, an improved myocardial remodelling after an ischemic insult with metformin use was indicated in a research (Varjabedian et al. 2018). A study in patients showed that the progression of the medial thickness of the carotid artery was reduced in metformin-treated diabetic patients. The median thickness of the carotid artery is a known indicator of atherosclerotic progression. It has also been indicated that activation of AMPK by metformin can have a pleiotropic effect (Zang et al. 2004a, b; Vasamsetti et al. 2015). Additionally, various studies have shown that treatment with metformin is effective in heart diseases, including cardiotoxicity (Kuburas et al. 2022, O’Neill et al. 2022, Park, Park et al. 2022), heart failure (Benes et al. 2022, Buczyńska et al. 2022, Hendawy et al. 2022), atrial fibrillation (Bai et al. 2019, Liu et al. 2020, Zhou et al. 2022), coronary heart disease (Hua et al. 2018, Luo et al. 2020).

**Therapeutic actions of metformin in reproductive system diseases**

In a research conducted by HyeRan Gwak et al. in 2017, the mechanism of action of metformin on ovarian cancer was examined. The results of this research confirmed that metformin can inhibit Akt and P70S6K by activating AMPK. Following this process, the GSK3β protein is activated, and finally during the ubiquitin/ proteasome process, the value
of cyclin D1 decreases. In fact, metformin decreases the amount of cyclin D1 without affecting its transcription levels (Gwak et al. 2017). Cyclin D1 is an essential regulator of the cell cycle in phase G1. Investigations have indicated that high expression of this factor is associated with resistance to treatment and prognosis of ovarian cancer (Bali et al. 2004; Hashimoto et al. 2011). Activation of AMPK by metformin in ovarian syndrome or metabolic syndrome in vitro and in vivo results in the inhibition of metabolism, cessation of the cell cycle, and finally apoptosis of cells (Ben Sahra et al. 2008; Pierotti et al. 2013). Research studies have shown that using metformin is associated with improved semen parameters and testicular weight, reduced apoptosis in testicular cell, and finally restoration of hormonal homeostasis (Yan, Mu et al. 2015a, b). Indeed, metformin administration in STZ-diabetic rats resulted in improved testosterone, LH and FSH hormones levels (Nasrolahi et al. 2013). Various studies have shown that treatment with metformin is effective in reproductive system diseases, including female and male reproduction in endocrine pathologies (Lee et al. 2019; Shpakov 2021, ul haq Shah, Shrivastava et al. 2022), endometriosis (Zhao et al. 2018, Mu et al. 2020, Stochino-Loi et al. 2021, Kimber-Trojnar et al. 2022), polycystic ovary syndrome (Chen et al. 2019; Fornes et al. 2022, Xu et al. 2022) and prostate (Sun et al. 2018, Chen, Wang et al. 2021a, b, c, Aydin et al. 2022, Morale et al. 2022).

Therapeutic actions of metformin in the bone structure

Available evidence suggests the occurrence of fibroblasts asphyxiation and blockage of AMPK activity in the ankylosing spondylitis disease. Moreover, laboratory investigations conducted on metformin have indicated its anti-osteogenic effects and also its agonist property concerning AMPK. Findings of the research carried out by Xiong Qin et al. in 2018 showed that osteogenic markers and inhibition of ossification are reduced significantly by metformin prescription to fibroblasts extracted from patients with ankylosing spondylitis (Qin et al. 2018a, b). Metformin is able to suppress the differentiation of osteoblasts and inhibit the signalling pathway of OPG/RANKL/RANK (Shao et al. 2014). In another study carried out in 2010, the mechanism of metformin’s activity on the differentiation of osteoblasts was examined. This research revealed that metformin could increase the expression of osteogenic genes such as bone sialoprotein, alkaline phosphatase, Runx2, osteocalcin, and SHP. Metformin induces the physical interaction and the formation of a complex between SHP and Runx2 in the osteocalcin promoter. The research findings showed that metformin might stimulate osteoblasts differentiation via changing the activation of Runx2 by upstream stimulatory factor-1 AMPK/USF-1/SHP (Jang et al. 2011). Min-Ji Ahn and Goang-Won Cho indicated, in a research conducted in 2017, that activation of AMPK by metformin could have a stimulatory role in human bone marrow mesenchymal stem cells towards neural differentiation (Ahn and Cho 2017).

Various studies have shown that treatment with metformin is effective in bone structure, including osteoarthritis (Feng et al. 2020; Li et al. 2020a, b; Li et al. 2020a, b), osteoporosis (Blümel et al. 2020, Guo et al. 2022, Song et al. 2022), bone regeneration (Ren et al. 2021; Fang et al. 2022; Sun et al. 2022) and osteosarcoma (Paiva-Oliveira et al. 2018; Zhao et al. 2019, Lu et al. 2021).

Therapeutic actions of metformin in digestive system diseases

Min-Jie Lin et al. showed that activation of the metformin / AMPK pathway could improve the non-alcoholic fatty liver disease in obese mice (Lin et al. 2017a, b). Stimulation of this pathway has a positive effect on the activity of the LXRα transcription factor. This factor results in the decreasing regulation of expression of apolipoprotein (Jakel et al. 2004; Shu et al. 2007; Shu et al. 2010; Gao et al. 2012). Hence, due to the influence on the reduction of its expression in the aforementioned process, metformin ameliorates this complication (Lin et al. 2017a, b). Another study revealed that metformin could play an inhibitory role in the cell proliferation of Esophageal squamous cell carcinomas by positive regulation of AMPK, P53, P21 and P27 (Cai et al. 2015). Metformin significantly reduces the severity of inflammatory bowel disease (IBD) via suppressing the signalling pathway of STAT3. As the expression of STAT3 transcription factor is increased in this disease, the TH17 phenotype and the production of inflammatory cytokines, particularly IL-17, IL-6 and TNF-α increase. Metformin can reduce the expression of STAT3 and increase the expression of P53 through the AMPK pathway, which is in the upstream of the mTOR transcription factor. Regulation of these conditions improves the clinical status of IBD patients by reducing inflammation (Shackelford and Shaw 2009, Micic et al. 2011, Gálvez 2014, Lee, Lee et al. 2015a, b). Furthermore, another investigation revealed that inhibiting the activation of the two pathways of STAT3 and NF-βB by AMPK has been effective in inhibiting the growth of pancreatic tumours (Tan et al. 2015). In addition, various studies have shown that treatment with metformin is effective in digestive system diseases, including colitis (El-Mahdy et al. 2021, Liu, Liao et al. 2021, El-Ghannam et al. 2022), Pancreatitis (He et al. 2021, Wang et al. 2021a, b, c, Wang, Yu et al. 2021), Liver Disease (Saeedi Saravi et al. 2016, Pinyopornpanish et al. 2021, Xie, Wang et al. 2021a, b, c) and Gut Microbiota (Lee, Chae et al. 2021b, a, Lee, Kim et al. 2021, Liu, Liao et al. 2021).
Conclusions

Many studies have investigated the role of metformin in the treatment of various diseases, including inflammatory diseases, autoimmune diseases and cancer. A considerable number of these investigations have revealed that the capacity of metformin to activate AMPK and also the consequent activation or inhibition of different factors by metformin enable it to alter the pathological pathways of the disease, direct cell differentiation, and moderate the inflammatory conditions. Since its therapeutic use, even at high doses, does not lead to severe side effects, metformin has a significant role in either treating various diseases or reducing their symptoms.

Funding The author have not disclosed any funding.

Data availability Enquiries about data availability should be directed to the authors.

Declarations

Conflict of interest The author have not disclosed any conflict of interest.

References

Afshari K, Dehdashtian A, Haddadi NS, Haj-Mirzaian A, Iranmehr A, Ebrahimi MA, Tavangar SM, Faghir-Ghanesefat H, Mohammadi F, Rahimi N, Javidan AN, Dehpour AR (2018) Anti-inflammatory effects of metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy. Spinal Cord 56(11):1032–1041

Ahm MJ, Cho GW (2017) Metformin promotes neuronal differentiation and neurite outgrowth through AMPK activation in human bone marrow-mesenchymal stem cells. Biotechnol Appl Biochem 64(6):836–842

Amarde G, Martínez-León E, Picco ME, Di Siervi N, Davio C, Rozengurt E, Rey O (2019) Metformin inhibits β-catenin phosphorylation on Ser-552 through an AMPK/PI3K/Akt pathway in colorectal cancer cells. Int J Biochem Cell Biol 112:88–94

An H, He L (2016) Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 228(3):R97–106

Apostolova N, Iannantuoni F, Gruveska A, Muntane J, Thornton C, Carling D (2009) The regulation and function of mammalian AMPK-related kinases. Acta Physiol (Oxf) 196(1):15–26

Arbeláez-Quintero I, Palacios M (2017) To use or not to use metformin in cerebral ischemia: a review of the application of metformin in stroke rodents. Stroke Res Treat 2017:9756429

Bai F, Liu Y, Tu T, Li B, Xiao Y, Ma Y, Qin F, Xie J, Zhou S, Liu Q (2019) Metformin regulates lipid metabolism in a canine model of atherial fibrillation through AMPK/PPAR-α/VLCAD pathway. Lipids Health Dis 18(1):1–9

Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM (2004) Cycinin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10(15):5168–5177

Bangi S, Barve R, Qamar A (2020) Protective effects of CVD and DM Medications in SARS-CoV-2 Infection. SN Compr Clin Med 2(9):1296–1298

Baur JA, Birnbaum MJ (2014) Control of gluconeogenesis by metformin: does redox trump energy charge? Cell Metab 20(2):197–199

Beladi Mousavi SS (2012) Metformin improves diabetic kidney disease. J Nephropharmacology 1(1):1–2

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auburger P, Tanti JF, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576–3586

Benes J, Kotrc M, Kroupova K, Wohlfahrt P, Kovar J, Frankova E, Hegarova M, L. Hoskova, E. Hoskova and T Pelikanova (2022) Metformin in the management of patients with diabetes and advanced heart failure (HF/EF): a propensity score-matched analysis

Benjamini A, Apaijai N, Chunchai T, Kerdphoo S, Jaiwongkam T, Arunsak B, Wongsuchai S, Chattipakorn N, Chattipakorn SC (2020) Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. Biochim et Biophys Acta (BBA) - Mol Basis Dis 1866(10):165893

Bhutta MS, Gallo ES, Borenstein R (2021) Multifaceted role of AMPK in viral infections. Cells 10(5):1118

Bielka W, Przeczek A, Pawlik A (2021) Therapy of type 2 diabetes in patients with SARS-CoV-2 infection. Int J Mol Sci 22(14):7605

Blümel JE, Arteaga E, Aedo S, Arriola-Montenegro J, López M, Martino M, Miranda C, Miranda O, Mostajo D, Nájera M, Ojeda E, Plinnik S, Rojas J, Salinas C, Sosa L, Spritzer PM, Tserotas K, Vallejo MS, Belardo A, Fighera TM, Chedraui P (2020) Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDILINC IX study. Gynecol Endocrinol 36(5):421–425

Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6):1304–1308

Borges C M, Fujihara C K, Malheiros D M A C, F V, de Ávila G, Formigari P, José B, de Faria L (2020) Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol- Renal Physiol 318(5):F1229–F1236

Brandaamer S, Xu T, Illig T, Suhre K, Adamski J, Wang-Sattler R (2015) Response to comment on Xu et al. effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. diabetes care 2015;38:1858–1867. Diabetes Care 38(12):e216–e217

Bright BJ, Thornton C, Carling D (2009) The regulation and function of mammalian AMPK-related kinases. Acta Physiol (oxf) 196(1):15–26

Buczylkońska A, Sidorkiewicz I, Krętowska M, Zbucka-Krętowska M, Adamksa A (2022) Metformin intervention—A panacea for cancer treatment? Cancers 14(5):1336

Cacicedo JM, Yagihashi N, Keaney JF Jr, Ruderman NB, Ido Y (2004) Metformin inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 324(4):1204–1209

A. Hasanvand

Springer
Cai X, Hu X, Tan X, Cheng W, Wang Q, Chen X, Guan Y, Chen C, Jing X (2015) Metformin induced AMPK activation, G0/G1 phase cell cycle arrest and the inhibition of growth of esophageal squamous cell carcinomas in vitro and in vivo. PLoS One 10(7):e0133349

Cai H, Zhang Y, Han TK, Everett RS, Thakker DR (2016) Cation-selective transporters are critical to the AMPK-mediated anti-proliferative effects of metformin in human breast cancer cells. Int J Cancer 138(9):2281–2292

Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85

Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, Maestre L, Conde E, Lopez-Rios F, Clevers HC, Sanchez-Cespedes M (2007) Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26(11):1616–1625

Chanda D, Li T, Song KH, Kim YH, Sim J, Lee CH, Chiang JY, Choi HS (2009) Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem 284(42):28510–28521

Chen SC, Brooks R, Housskee J, Bremner SK, Dunlop J, Viollet B, Logan PJ, Salt IP, Ahmed SF, Waroyd SJ (2017) Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. Mol Cell Endocrinol 440:57–68

Chen Z, Wei H, Zhao X, Xin X, Peng L, Ning Y, Wang Y, Lan Y, Zhang Q (2019) Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways. J Cell Physiol 234(11):19964–19976

Chiang CF, Chao TT, Su YF, Hsu CC, Chien CY, Chiu KC, Shiah SG, Lee CH, Liu SY, ShiehYS (2017) Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-kappaB signaling. Oncotarget 8(13):20706–20718

Choi JS, Park C, Jeong JW (2010) AMP-activated protein kinase is activated in Parkinson’s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun 391(1):147–151

Chung MM, Nicol CJ, Cheng YC, Lin KH, Chen YL, Pei D, Lin CH, Shih YN, Yen CH, Chen SJ, Huang RN, Chiang MC (2017) Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs. Exp Cell Res 352(1):75–83

Currie CJ, Poole CD, Everett RS, Thakker DR (2016) Cation-selective transporters are critical to the AMPK-mediated anti-proliferative effects of metformin in human breast cancer cells. Int J Cancer 138(9):2281–2292

Driver C, Hayangah JA, Nyane NA, Owira PMO (2018) Metformin with insulin relieves oxidative stress and confers renoprotection in type 1 diabetes in vivo. J Nephropathol 7(3):171–181

Duca FA, Cote CD, Rassmussen BA, Zadeh-Tahmasebi M, Rutter GA, Filippi BM, Lam TK (2015) Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats. Nat Med 21(5):506–511

El-Ghannam MS, Saad MA, Nassar NN, El-Yamamy MF, El-Bahy AA (2022) Linagliptin ameliorates acetic acid-induced colitis via modulating AMPK/SIRT1/PGC-1α and JAK2/STAT3 signaling pathway in rats. Toxicol Appl Pharmacol 438:115906

El-Mahdy NA, El-Sayad ME-S, El-Kadem AH, Abu-Risha SE-S (2021) Metformin alleviates inflammation in an experimental osteoarthritis model by regulating AMPK/autophagy. Aging (Albany NY) 13(1):1025–1039

El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X, Pouyet C, Ylstra B, He Q (2015) Metformin prevents cancer metastasis by inhibiting mTOR and NF-kappaB signaling. Br J Cancer 112(7):1080–1088

Esam Z (2020) A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19. Diabetes Res Clin Pract 167:108282

Fan Y-Y, Wang Y-J, Guo J, Wu M-N, Zhang M-S, Niu B-L, Li Y, Zhao J, Yang C-H, Li Y (2020) Delayed metformin treatment improves functional recovery following traumatic brain injury via central AMPK-dependent brain tissue repair. Brain Res Bull 164:146–156

Fang C-H, Sun C-K, Lin Y-W, Hung M-C, Lin H-Y, Li C-H, Lin I-P, Chang H-C, Sun J-S, Chang JZ-C (2022) Metformin-incorporated gelatin/nano-hydroxyapatite scaffolds promotes bone regeneration in critical size rat alveolar bone defect model. Int J Mol Sci 23(1):558

Feng X, Pan J, Li J, Zeng C, Qi W, Shao Y, Liu X, Liu L, Xiao G, Zhang H (2020) Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR. Aging (Albany NY) 12(2):1087

Fornes R, Simin J, Nguyen MH, Cruz G, Crisosto N, van der Schaf M, Engstrand L, Brusselaers N (2022) Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study, Reprod Biol Endocrinol 20(1):1–12

Gálvez J (2014) Role of Th17 cells in the pathogenesis of human IBD. Int Sch Res Notices

Gao X, Forte TM, Ryan RO (2012) Influence of apolipoprotein A-V on hepatocyte lipid droplet formation. Biochem Biophys Res Commun 427(2):361–365

Goodman WA, Young AB, McCormick TS, Cooper KD, Levine AD (2011) Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol 186(6):3336–3345

Green AS, Chapuis N, Maciel TT, Willems SM, Van der Schaf M, Engstrand L, Brusselaers N (2022) Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. Reprod Biol Endocrinol 20(1):1–12

Groenendijk FH, Mellema WW, van der Burg E, Schut E, Huisman M, Bremmer R (2015) Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer 136(6):1434–1444

The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new...
Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, Liu X-Q, Chen R-C, C-J, Tang and T, Wang. (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55(5):2000547

Guo Y, Yang R, Zong S, Wang Z, Zhao J, Chen C, Wang C, Wang S (2022) Metformin combined with aldendrone ameliorates osteoarthritis by attenuating RANKL-induced bone resorption and protecting cartilage against degradation

Gwk H, Kim Y, An H, Dhanasekaran DN, Song YS (2017) Metformin induces degradation of cyclin D1 via AMPK/GSK3beta axis in ovarian cancer. Mol Carcinog 56(2):349–359

Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30(2):214–226

Han Y-C, Tang S-Q, Liu Y-T, Liu A-M, Zhan M, Yang M, Song N, Zhang W, Wu X-Q, Peng C-H, Zhang H, Yang S (2021) AMPK agonist alleviates renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice. Cell Death Dis 12(10):925

Harada S, Fujita-Hamabe W, Tokuyama S (2010) The importance of the renin-angiotensin system and different mediators in diabetic nephropathy. Brain Res 1351:254–263

Hardie DG (2015) AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol 33:1–7

Hasanvand A (2018) Antioxidative and anti-inflammatory effects of metformin: a new look to an old drug. J Renal Endocrinol 4(1):2–2

Hasanvand A, Saberi S (2018) Renin angiotensin system and different mediators induce renal fibrosis. J Renal Endocrinol 4(1):9–9

Hasanvand A, Amini-Khoei H, Hadian MR, Abdollahi A, Tavangar SM, Dephoure AR, Semiei E, Mehr SE (2016) Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic nephropathy. Inflammopharmacology 24(5):207–219

Hasanvand A, Amini-Khoei H, Jahanabi S, Hadian M-R, Abdollahi A, Tavangar SM, Jemaei Mehr S, Dephoure AR (2018) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through activation of AMPK signaling pathway. J Nephropathol 7(1):37–42

Hashimoto T, Yanaihara N, Okamoto A, Nikaido T, Saito M, Takakura S, Yasuda M, Sasaki H, Ochiai K, Tanaka T (2011) Cyclin D1 predicts the prognosis of advanced serious ovarian cancer. Exp Ther Med 2(2):213–219

He L, Sabet A, Djejdovs S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137(4):635–646

He X, Gao F, Hou J, Li T, Tan J, Wang C, Liu X, Wang M, Liu H, Chen Y (2021) Metformin inhibits MAPK signaling and rescues pancreatic acinar protein 7 expression to induce insulin secretion in type 2 diabetes mellitus. J Biol Chem 297(2):101002

Hendawy M, Ramy A and Mohie I. (2022). “Autophagy promotion and fibrosis inhibition by combination of GLP1 analogue and metformin decreasing the progression of type II diabetic cardiomyopathy of albino rats: immunohistochemical study.” Bull Egypt Soc Physiol Sci. 202–212

Hills CE, Squires PE (2011) The role of TGF-beta and epithelial-to-mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22(3):131–139

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271-280.e278

Hua J, Liu Z, Liu Z, An D, Lai W, Zhan Q, Zeng Q, Ren H, Xu D (2018) Metformin increases cardiac rupture after myocardial infarction via the AMPK-MTOR/PGC-1α signaling pathway in rats with acute myocardial infarction. Med Sci Monit: Int Med J Exp Clin Res 24:6989

Huang BP, Lin CH, Chen HM, Lin JT, Cheng YF, Kao SH (2015) AMPK activation inhibits expression of proinflammatory mediators through downregulation of PI3K/p38 MAPK and NF-kappB signaling in murine macrophages. DNA Cell Biol 34(2):133–141

Ibrahim S, Lowe JR, Bramante CT, Shah S, Klatt NR, Sherwood N, Aronne L, Puskarich M, Tamariz L, Palacio A, Bomberg E, Usher M, King S, Benson B, Vojta D, Tignaneli C, Ingraham N (2021) Metformin and Covid-19: focused review of mechanisms and current literature suggesting benefit. Front Endocrinol (Lausanne) 12:587801

Israel AA, Espinosa-Olivia AM, Santiago M, Garcia-Quintanilla A, Oliva-Martin MJ, Herrera AJ, Venero JL, de Pablos RM (2016) Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system. Toxicol Appl Pharmacol 298:19–30

Jaku H, Nowak M, Moitrot E, Dehondt H, Hum DW, Pennacchio LA, Fruchtch-Najib J, Fruchtart JC (2004) The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 279(44):45462–45469

Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK, Kim SH, Lee CH, Franscher RT, Choi HS, Koh JT (2011) Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48(4):885–893

Jin X, Yao T, Zhou Z, Zhu XJ, Zhang S, Hu W, Shen C (2015) Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-κB pathway. BioMed Res Int 2015:12

Johanns M, Lai Y-C, Hsu M-F, Jacobs R, Vertommen D, Van Sande J, Dumont JE, Woods A, Carling D, Hue L (2016) AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B. Nat Commun 7(1):1–12

Kamyshnyi O, Matiskevych V, Lenchuk T, Strilbytska O, Storey K, Lushchak O (2021) Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Biomed Pharmacother 144:112230

Karnewar S, Neeli PK, Panuganti D, Kotagiri S, Mallappa S, Jain N, Jerald MK, Kotamraju S (2018) Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: relevance in age-associated vascular dysfunction. Biochim Biophys Acta 1864((4.Pt A)):1115–1128

Kim JD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jiang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57(2):306–314

Kim HG, Hien TT, Han EH, Hwang YP, Cho CH, Kang KW, Kwon K, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG (2011) Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162(5):1096–1108

Kimber-Trojnar Ż, Dłuski DF, Wierzchowska-Opoka M, Ruszała M, Lushchak O (2021) Metformin and Covid-19: focused review of mechanisms and current literature suggesting benefit. Front Endocrinol (Lausanne) 12:587801

Kuburas R, Gharanei M, Haussmann I, Maddock H, Sandhu H (2022) Metformin protects against sunitinib-induced cardiotoxicity:
investigating the role of AMPK: Investigating the role of AMPK. Authorea Preprints

Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, Cho ML (2015a) Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance. PLoS One 10(9):e0135858

Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, Cho ML (2015b) Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance. PLoS One 10(9):e0135858

Lee SY, Moon SJ, Kim EK, Seo HB, Yang EJ, Son HJ, Kim JK, Min JK, Park SH, Cho ML (2017) Metformin suppresses systemic autoimmunity in roquin(san/san) Mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK/mTOR/STAT3. J Immunol 198(7):2661–2670

Lee JW, Shin Y-J, Kim H, Kim H, Kim J, Min S-A, Kim P, Do Yu S, Park K (2019) Metformin-induced endocrine disruption and oxidative stress of Oryzae latipes on two-generational condition. J Hazard Mater 367:171–181

Lee CB, Chae SU, Jo SJ, Jerng UM, Bae SK (2021a) The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. Int J Mol Sci 22(7):3566

Lee Y, Kim AH, Kim E, Lee S, Yu K-S, Jang I-J, Chung J-Y, Cho J-Y (2021) Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids. Diabetes Res Clin Pract 178:108985

Leech T, Apaijai N, Palee S, Higgins LA, Chattipakorn SC, Chattipakorn N, Chattipakorn SC (2020) Acute administration of metformin prior to cardiac ischemia/reperfusion injury protects brain injury. Eur J Pharmacol 885:173418

Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137(2):482–488

Li KL, Li L, Zhang P, Kang J, Wang YB, Chen HY, He Y (2017) A multicenter double-blind phase II study of metformin with Gefitinib as first-line therapy of locally advanced non-small-cell lung cancer. Clin Lung Cancer 18(3):340–343

Li H, Ding X, Terkeltaub R, Lin H, Zhang Y, Zhou B, He K, Li K, Liu Z, Wei J (2020a) Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior. Arthritis Res Ther 22(1):1–11

Li J, Zhang B, Liu W-X, Lu K, Pan H, Wang T, Yi D, Huang J, Zhao L, Ning G (2020b) Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis 79(5):635–645

Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC (2013) Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol 49(2):241–250

Lin MJ, Dai W, Scott MJ, Li R, Zhang YQ, Yang Y, Chen LZ, Huang XS (2017a) Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRx signaling pathway. Oncotarget 8(65):108802–108809

Lin MJ, Dai W, Scott MJ, Li R, Zhang YQ, Yang Y, Chen LZ, Huang XS (2017b) Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRx signaling pathway. Oncotarget 8(65):108802–108809

Liu Y, He C, Huang X (2017) Metformin partially reverses the carbohydrate-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget 8(43):75206–75216

Liu Y, Bai F, Liu N, Zhang B, Qin F, Tu T, Li B, Li J, Ma Y, Ouyang F (2020) Metformin improves lipid metabolism and reverses the Warburg effect in a canine model of chronic atrial fibrillation. BMC Cardiovasc Disord 20(1):1–9

Lu J, Shi J, Li M, Gui B, Fu R, Yao G, Duan Z, Lv Z, Yang Y, Chen Z, Jia L, Tian L (2015) Activation of AMPK by metformin inhibits TGF-beta-induced collagen production in mouse renal fibroblasts. Life Sci 127:59–65

Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G (2016) Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson’s disease via autophagy and mitochondrial ROS clearance. Int J Neurosychopharmacol 19(9):pyw047

Lu M, Chen H, Nie F, Wei X, Yao Z, Ma J (2020) The potential role of metformin in the treatment of Parkinson’s disease. J Bio-X Res 3(01):27–35

Lu G, Wu Z, Shang J, Xie Z, Chen C, C. zhang, (2021) The effects of metformin on autophagy. Biomed Pharmacother 137:111286

Luo T, Nocon A, Fry J, Sherban A, Rui X, Jiang B, Xu XJ, Han J, Yan Y, Yang Q, Li Q, Zang M (2016) AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes 65(8):2295–2310

Luo Z, Zhu T, Luo W, Lv Z, Zhang L, Wang C, Li M, Wu W, Shi S (2019) Metformin induces apoptotic cytotoxicity depending on AMPK/PAK/GSK-3β-mediated c-FLIP(L) degradation in non-small cell lung cancer. Cancer Manag Res 11:681–689

Luo S, Schooling CM, Wong IKC, Au Yeung SL (2020) Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study. Diabetologia 63(11):2349–2358

Ma J, Yu H, Liu J, Chen Y, Wang Q, Xiang L (2015) Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. Eur J Pharmacol 764:599–606

Maddour MS, Miossec P, Kaveri SV, Bayrj J (2012) Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181(1):8–18

Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S (2004) Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 64(3):225–228

Melemedjian OK, Yassine HN, Shay A, Price T (2013) Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment. Mol Pain 9:14

Miao D, Covic Jovivic G, Trajovic V, Duntas LH, Polovina S (2011) Metformin: its emerging role in oncology. Hormones (athens) 10(1):5–15

Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494(7436):256–260

Miura S, Takahashi K, Imagawa T, Uchida K, Saito S, Tominaga M, Ohta T (2013) Involvement of TRPA1 activation in acute pain induced by cadmium in mice. Mol Pain 9:7

Mo C, Wang L, Zhang J, Numazawa S, Tang H, Tang X, Han X, Li J, Yang M, Wang Z, Wei D, Xiao H (2014) The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. Antioxid Redox Signal 20(4):574–588

Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV (2013) Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Trans Oncol 6(6):649–659

Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnl, Sedlnskys C (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 25(2):211–221
Morale MG, Tamura RE, Rubio IGS (2022) Metformin and cancer hallmarks: molecular mechanisms in thyroid, prostate and head and neck cancer models. Biomolecules 12(3):357

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D’Alito E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F (2013) Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 19(13):3508–3519

Mu N, Xu T, Gao M, Dong M, Tang Q, Hao L, Wang G, Li Z, Wang W, Yang Y (2020) Therapeutic effect of metformin in the treatment of endometrial cancer. Oncol Lett 20(5):1–1

Mukhtar RA, Nseyo O, Campbell MJ, Isserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11(1):91–100

Mummidi S, Das NA, Carpenter AJ, Kandikattu H, Krenz M, Siebenlist U, Valente AJ, Chandrasekar B (2016) Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol 98:95–102

N HS, P YN, K KL (2019) Envisioning the neuroprotective effect of metformin in experimental epilepsy: a portrait of molecular crosstalk. Life Sci 233:116686

Nasrolahi O, Khaeheh F, Rahmani F, Razi M (2013) Honey and metformin ameliorated diabetes-induced damages in testes of rat; correlation with hormonal changes. Iran J Reprod Med 11(12):1013–1020

Nazim UM, Moon HJ, Lee HJ, Lee YJ, Seol JW, Eo SK, Lee JH, Park K (2016) Activation of autophagy flux by metformin down-regulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis. Oncotarget 7(17):23468–23481

O’Neill EJ, Moore J, Song J, Tsiani EL (2022) Inhibition of non-small cell lung cancer proliferation and survival by rosemary extract is associated with activation of ERK and AMPK. Life 12(1):52

Oakhill JS, Scott JW, Kemp BE (2009) Structure and function of AMP-activated protein kinase. Acta Physiol (oxf) 196(1):3–14

Oliveria SA, Koro CE, Yood MU, Sowell M (2008) Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr 2(1):47–57

Paiva-Oliveira DI, Martins-Neves SR, Abrunhosa AJ, Fontes-Ribeiro C, Gomes CM (2018) Therapeutic potential of the metabolic modulator metformin on osteosarcoma cancer stem-like cells. Cancer Chemother Pharmacol 81(1):49–63

Park SY, Kim D, Kee SH (2019) Metformin-activated AMPK regulates β-catenin to reduce cell proliferation in colon carcinoma RKO cells. Oncol Lett 17(3):2695–2702

Park J-W, Park J-E, Kim S-R, Sim M-K, Kang C-M, Kim KS (2022) Metformin alleviates ionizing radiation-induced senescence by restoring BARD1-mediated DNA repair in human aortic endothelial cells. Exp Gerontol 111706

Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levandi T, Martinelli E, De Vita F, Orditura M, De Palma R, Di Nunzio S, Alstad AN, Levandi T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F (2013) Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 19(13):3508–3519

Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S (2014) Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. Neuroscience 277:747–754

Paudel YN, Angelopoulou E, Piperi C, Shaikh MF, Othman I (2020) Metformin ameliorated diabetes-induced damages in testes of rat; correlation with hormonal changes. Iran J Reprod Med 18(12):8633–8641

Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y (2012) Astragalus membranaceus inhibits inflammation via Phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear Factor (NF)-κB pathways in advanced glycation end product-stimulated macrophages. Int J Mol Sci 13(7):8379–8387

Qin W, Gao X, Ma T, Weir MD, Zou J, Song B, Lin Z, Schneider A, Xu HHK (2018a) Metformin enhances the differentiation of dental pulp cells into odontoblasts by activating AMPK signaling. J Endod 44(4):576–584

Qin X, Jiang T, Liu S, Tan J, Wu H, Zheng L, Zhao J (2018b) Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: An in vitro study. J Cell Biochem 119(1):1074–1082

Rafieian-Kopaei M (2013) Combination of metformin with other anti-oxidants may increase its renoprotective efficacy. J Renal Inj Prev 2(2):35–36

Rahimi S, Fardowski A, Siahposht-Khachaki A (2020) Neuroprotective effects of metformin on traumatic brain injury in rats is associated with the AMP-activated protein kinase signaling pathway. Metab Brain Dis 35(7):1135–1144

Salt IP, Palmer TM (2012) Exploiting the anti-inflammatory effects of metformin in a million efficient medicines for rheumatoid arthritis complications: inflammation, osteoarthritis, cardiovascular disease, malignancies. Curr Rheumatol Rev 15:116–122

Ramaiah MJ (2020) mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19. Gene Rep 20:100765

Rehill JA, Ewart MA, Hardie DG, Salt IP (2007) AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem Biophys Res Commun 354(4):1084–1088

Ren C, Hao X, Wang L, Hu Y, Meng L, Zheng S, Ren F, Bu W, Wang H, Li D (2021) Metformin Carbon Dots for promoting periodontal bone regeneration via activation of ERK/AMPK pathway. Adv Healthcare Mater 10(12):2100196

Ruijer R, Visser LE, van Herk-Sukel MP, Koopmans WP, Coebergh JW, Haak HR, Strain U, Valente AJ, Chandrasekar B (2016) Metformin inhibits β-catenin to reduce cell proliferation in colon carcinoma RKO cells. Oncol Lett 17(3):2695–2702

Salt IP, Palmer TM (2012) Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 21(8):1155–1167

Salvati KA, Ritter ML, Davoudian PA, O’Dell F, Wyskiel DR, Souza GMPR, Lu AC, Perez-Reyes E, Drake JC, Yan Z, Beenharker 786

Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S (2013) Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32(12):1475–1487

Pinyopornpanich K, Leerapun A, Pinyopornpanich K, Chattipakorn N (2021) Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut and Liver 15(6):827

Pulito C, Donzelli S, Mutti P, Puzzo L, Strano S, Blandino G, Giorgi C, Gomes CM (2018) Therapeutic potential of the metabolic modulator metformin on osteosarcoma cancer stem-like cells. J Mol Med (berl) 89(7):667–676
The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new…

MP (2022) AMPK-mediated potentiation of GABAergic signaling drives hypoglycaemia-provoked spike-wave seizures. Brain. https://doi.org/10.1093/brain/awac037

Santi SA, Lee H (2011) Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS One 6(1):e14614

Sanz P, Serratosoa JM, Sánchez MP (2021) Beneficial effects of metformin on the central nervous system, with a focus on epilepsy and Lafora disease. Int J Mol Sci 22(10):5351

Sarai P, Asadi I, Kakar MA, Moradi-Kor N (2019) The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res 11:3295–3313

Seo Y, Kim J, Park SJ, Park JJ, Cheon JH, Kim WH, Kim TI (2020) Metformin suppresses cancer stem cells through AMPK activation and inhibition of protein prenylation of the mevalonate pathway in colorectal cancer. Cancers 12(9):2554

Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9(8):563–575

Shao X, Cao X, Song G, Zhao Y, Shi B (2014) Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation. J Diabetes Res 2014:453940

Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bandeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5755):1642–1646

Shen H, Zhang J, Wang C, Jain PP, Xiong M, Shi X, Lei Y, Chen S, Yin Q, Thistlethwaite PA, Wang J, Gong K, Yuan ZY, Yuan JX, Shyy QY (2020) MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension. Circulation 142(12):1190–1204

Shpakov AO (2011) Mechanism of AMPK. Am J Physiol Endocrinol Metab 311(4):E730-e740

Shakirzadeh S, Rouini M-R, Najafi A, Heshmat R, Abdollahi M, Mojtabahzadeh M (2019) A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury. J Neurol Neurosurg Psychiatry 86(6):1988–1997

Taleb S, Moghaddas P, Rahimi Balae M, Taleb S, Rahimpour S, Abbasi A, Ehtemaei-Mehr S, Dehpour AR (2014) Metformin improves skin flap survival through nitric oxide system. J Surg Res 192(2):686–691

Taheri A, Emami M, Asadipour E, Kasirzadeh S, Rouini M-R, Najafi A, Heshmat R, Abdollahi M, Mojtabahzadeh M (2019) A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury. J Neurol Neurosurg Psychiatry 86(6):1988–1997

Taleb S, Moghaddas P, Rahimi Balae M, Taleb S, Rahimpour S, Abbasi A, Ehtemaei-Mehr S, Dehpour AR (2014) Metformin improves skin flap survival through nitric oxide system. J Surg Res 192(2):686–691

Taylor A, Westveld AH, Szkudlinska M, Guruviri P, Annabi E, Patwardhan A, Price TJ, Yassine HN (2013) The use of metformin is associated with decreased lumbar radiolucity of the neck. J Pain Res 6:755–763

Tkachev VO, Menshchikova EB, Zenkov NK (2011) Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (mosc) 76(4):407–422

Ul haq Shah MZ, Shrivastava V, Mir MA (2022) Metformin treatment ameliorates endocrine-metabolic disturbances in luteinized-induced PCOS mice model by modulating adiponectin status. Obesity 266(8):e100392

Varjabedian L, Bourji M, Pourafkari L, Nader ND (2018) Cardioprotective by metformin: beneficial effects beyond glucose reduction. Am J Cardiovasc Drugs 18(3):181–193

Vasamsetti SB, Karnewar S, Kanugula AK, Thathipalli AR, Kumar JM, Kotamraju S (2015) Metformin inhibits monocye-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64(6):2028–2041

Vazquez-Martinez A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA (2009a) AMPK: evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle 8(22):3679–3683

Vazquez-Martinez A, Oliveras-Ferraros C, Menendez JA (2009b) The anti diabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8(1):88–96

Wang C, Liu C, Gao K, Zhao H, Zhou Z, Shen Z, Guo Y, Li Z, Yao T, Mei X (2016) Metformin preconditioning provide neuroprotection through enhancement of autophagy and suppression of inflammation and apoptosis after spinal cord injury. Biochem Biophys Res Commun 477(4):534–540

Springer
Wang X, Chen K, Yu Y, Xiang Y, Kim JH, Gong W, Huang J, Shi G, Li Q, Zhou M, Sayers T, Tewary P, Gao B, Wang JM (2017) Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. Oncotarget 8(65):109068–109078

Wang S, Kobayashi K, Kogure Y, Yamanaka H, Yamamoto S, Yagi H, Noguchi K, Dai Y (2018) Negative regulation of TRPA1 by AMPK in primary sensory neurons as a potential mechanism of painful diabetic neuropathy. Diabetes 67(1):98–109

Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D, Wu C, Zhao Y (2021a) Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HIF1G upregulation. Protein Cell 12(2):128–144

Wang L, Wang A, Guo H, Zhang Z, Wang S, Pei T, Liu Z, Yang D, Liu Y, Ruan C (2021b) Neuroprotective effects of long-term metformin preconditioning on rats with ischemic brain injuries. Eur Neurol 84(3):212–218

Wang X-D, Yu W-L, Sun Y (2021) Activation of AMPK restored impaired autophagy and inhibited inflammation reaction by upregulating SIRT1 in acute pancreatitis. Life Sci 277:119435

Weichhart T, Saemann MD (2009) The multiple facets of mTOR in immunity. Trends Immunol 30(5):218–226

Wiernsperger N (2015) Metformin as a cellular protector; a synoptic view of modern evidences. J Nephropharmacol 4(1):31–36

Witzig TE, Gupta M (2010) Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010:265–270

Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, Guo X, Guo T, Botchelt R, Qi T, Pei Y, Zheng J, Xu Y, An X, Chen L, Chen L, Li Q, Xiao X, Hua Y, Wu C (2014) Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One 9(3):e91111

Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20(9):1617–1622

Xu, B, Dai W, Liu L, Han H, Zhang J, Du X, Pei X and Fu X (2022) "Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway" Endocrine J EJ21–0480.

Yan H, Zhou H, Hu Y, Pham CTN (2015) Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J Rheum Dis Treat 1(1):5

Yan W, Mu Y, Yu N, Yi T, Zhang Y, Pang X, Cheng D, Yang J (2015b) Protective effects of metformin on reproductive function in obese male rats induced by high-fat diet. J Assit Reprod Genet 32(7):1097–1104

Yang Z, Kahn BB, Shi H, Xue BZ (2010) Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285(25):19051–19059

Yang X, Ding H, Qin Z, Zhang C, Qi S, Zhang H, Yang T, He Z, Yang K, Du E, Liu C, Xu Y, Zhang Z (2016) Metformin prevents renal stone formation through an antioxidant mechanism in vitro and in vivo. Oxid Med Cell Longev 2016:10

Yerra VG, Kalvala AK, Sherkhane B, Areti A, Kumar A (2018) Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy. Neuropharmacology 131:256–270

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.